Stifel Nicolaus Begins Coverage on Altimmune (NASDAQ:ALT)

Stifel Nicolaus assumed coverage on shares of Altimmune (NASDAQ:ALT) in a report issued on Wednesday morning, MarketBeat reports. The brokerage issued a buy rating and a $18.00 price target on the stock.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, November 14th. UBS Group initiated coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.71.

Altimmune Trading Down 7.8 %

Shares of ALT stock opened at $6.87 on Wednesday. The stock has a market cap of $488.63 million, a price-to-earnings ratio of -4.43 and a beta of 0.22. The stock has a 50-day moving average of $8.10 and a 200-day moving average of $7.20. Altimmune has a 1-year low of $5.28 and a 1-year high of $14.84.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period in the previous year, the company posted ($0.39) EPS. Sell-side analysts forecast that Altimmune will post -1.36 earnings per share for the current year.

Institutional Investors Weigh In On Altimmune

Large investors have recently added to or reduced their stakes in the business. B. Riley Wealth Advisors Inc. grew its stake in Altimmune by 12.9% in the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock valued at $144,000 after acquiring an additional 2,687 shares during the period. Virtu Financial LLC acquired a new stake in Altimmune in the third quarter valued at approximately $674,000. Barclays PLC grew its stake in Altimmune by 93.0% in the third quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after acquiring an additional 75,064 shares during the period. Geode Capital Management LLC grew its stake in Altimmune by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after acquiring an additional 74,194 shares during the period. Finally, Wellington Management Group LLP grew its stake in Altimmune by 27.5% in the third quarter. Wellington Management Group LLP now owns 197,232 shares of the company’s stock valued at $1,211,000 after acquiring an additional 42,553 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.